Invitrogen™ MegaScript™ T7 Transcription Kit Plus
Achieve ultra-high RNA yields with MEGAscript™ kits—ideal for in vitro or in vivo translation studies needing unlabeled or low specific activity RNA.
Receive your quote directly from the manufacturer.
The MegaScript T7 Transcription Kit Plus contains all the reagents and buffers necessary for in vitro synthesis of large amounts of RNA. Each 20-μL reaction yields an average of 100 μg of RNA, while the scaled-up protocol yields up to 1 mg of RNA. This kit is suitable for full- or partially-modified-nucleotide substitution to produce modified RNA. It is also suitable for co-transcriptional capping with cap analogs to make capped RNA that can be translated into protein.
Features of the MegaScript T7 Transcription Kit Plus include:
- Optimized to achieve high mRNA yields (>5 mg/mL)
- Flexible—allows use of modified nucleotides and/or cap analogs such as ARCA or CleanCap
- Includes GFP control template
- Made up of high quality reagents (TheraPure)
- Available in two sizes: 50 and 1000 reactions
The MegaScript T7 Transcription Kit Plus requires a linearized DNA template with a T7 RNA polymerase promoter to create >5 mg/mL of RNA. MEGAscript kits are intended for the synthesis of large amounts of unlabeled or low-specific-activity RNA for a variety of uses, including transfections, preclinical mRNA therapeutic mRNA studies, microinjections, in vitro translation, and RNA structure and function analysis. Note that this kit does not create capped RNA, which is necessary for translational studies. MEGAscript kits are not recommended for synthesis of high-specific-activity probes.
Invitrogen in vitro transcription kits - Flexible solutions to synthesize potent mRNA
With over 50,000 citations, the proven suite of Invitrogen™ in vitro transcription (IVT) kits are recognized as the most reliable and highest-performing reagents in the industry. In this application note, Thermo Fisher Scientific provides a guide to help you choose the kit that aligns with your experimental goals.
Generating high-quality mRNA-LNP complexes for in vivo delivery: Strategies and methods
Thursday, May 29, 2025 - 9:30 IST | 12:00 SGT | 13:00 KST, JST | 14:00 AEST
The production of high-quality mRNA for therapeutic applications presents several challenges, including yield limitation, low capping efficiency, stability concerns, and immunogenicity issues. In fact, crude mRNA preparations can trigger transient inflammatory responses, complicating their use in clinical settings.
In this expert webinar, we will discuss the latest advancements in mRNA synthesis, purification, and delivery technologies that are helping to overcome these barriers. This session will provide a practical walkthrough of using the mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG to achieve efficient co-transcriptional capping and generate high-yield, high-purity mRNA with minimal immunogenic contaminants.
You’ll also discover how Vivofectamine delivery solutions are utilized to encapsulate mRNA into lipid nanoparticles (LNPs) for stable and targeted in vivo delivery. We’ll highlight methods to assess the performance, expression, and immunogenic profile of these mRNA-LNP complexes through in vitro and in vivo assays, including luciferase reporter expression in mouse models.
Key learning objectives:
- Learn key steps in mRNA synthesis and purification
- Discover basic concepts and components in the formulation of LNPs
- Gain practical insights and protocols to enhance the efficacy and safety of mRNA-based treatments
Who should attend?
Researchers and professionals involved in mRNA therapeutics or applications.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
